p38γ mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription

Journal of Biological Chemistry

Volumn 287, Issue 18, 2012, Pages 14681-14691

  Qi, Xiaomei ^a   Zhi, Huiying ^a   Lepp, Adrienne ^a   Wang, Phillip ^a   Huang, Jian ^a   Basir, Zainab ^a   Chitambar, Christopher R ^a   Myers, Charles R ^a   Chen, Guan ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-ESTROGENS; BREAST CANCER; ESTROGEN RECEPTOR; ESTROGEN RESPONSE ELEMENTS; MITOGEN ACTIVATED PROTEIN KINASE; SIGNALING CASCADES; SIGNALING EVENTS; SIGNALING TRANSDUCTION; TAMOXIFEN;

BINDING SITES; PHOSPHORYLATION; TRANSCRIPTION;

SIGNALING;

ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 12; PROTEIN C JUN; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1;

AMINO ACID COMPOSITION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE SWITCHING; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 12; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; RESPONSE ELEMENTS; TAMOXIFEN; TRANSCRIPTION, GENETIC;

EID: 84860370781     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.349357     Document Type: Article

References (57)

1. Hall, J. M., Couse, J. F., and Korach, K. S. (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276, 36869-36872
2. Glidewell-Kenney, C., Weiss, J., Lee, E. J., Pillai, S., Ishikawa, T., Ariazi, E. A., and Jameson, J. L. (2005) ERE-independent ERα target genes differentially expressed in human breast tumors. Mol. Cell. Endocrinol. 245, 53-59
3. Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., and Hilakivi-Clarke, L. (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22, 7316-7339
4. Jordan, V. C., and O'Malley, B. W. (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25, 5815-5824
5. Ishii, Y., Waxman, S., and Germain, D. (2008) Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res. 68, 852-860
6. Bedard, P. L., Freedman, O. C., Howell, A., and Clemons, M. (2008) Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Res. Treat 108, 307-317
7. Walters, M. R., Dutertre, M., and Smith, C. L. (2002) SKF-82958 is a subtype-selective estrogen receptor-α (ERα) agonist that induces functional interactions between ERα and AP-1. J. Biol. Chem. 277, 1669-1679
8. Klinge, C. M., Blankenship, K. A., Risinger, K. E., Bhatnagar, S., Noisin, E. L., Sumanasekera, W. K., Zhao, L., Brey, D. M., and Keynton, R. S. (2005) Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors α and β in endothelial cells. J. Biol. Chem. 280, 7460-7468
9. Kronblad, A., Hedenfalk, I., Nilsson, E., Påhlman, S., and Landberg, G. (2005) ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced down-regulation of ERα: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 24, 6835-6841
10. Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., Metzger, D., and Chambon, P. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-1494
11. Chen, D., Riedl, T., Washbrook, E., Pace, P. E., Coombes, R. C., Egly, J. M., and Ali, S. (2000) Activation of estrogen receptor α by Ser-118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol. Cell 6, 127-137
12. Valley, C. C., Métivier, R., Solodin, N. M., Fowler, A. M., Mashek, M. T., Hill, L., and Alarid, E. T. (2005) Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor α N terminus. Mol. Cell. Biol. 25, 5417-5428
13. Cheng, J., Zhang, C., and Shapiro, D. J. (2007) A functional serine 118 phosphorylation site in estrogen receptor-α is required for down-regulation of gene expression by 17β-estradiol and 4-hydroxytamoxifen. Endocrinology 148, 4634-4641
14. Kok, M., Holm-Wigerup, C., Hauptmann, M., Michalides, R., Stål, O., Linn, S., and Landberg, G. (2009) Estrogen receptor-α phosphorylation at serine-118 and tamoxifen response in breast cancer. J. Natl. Cancer Inst. 101, 1725-1729
15. Chen, D., Washbrook, E., Sarwar, N., Bates, G. J., Pace, P. E., Thirunuvakkarasu, V., Taylor, J., Epstein, R. J., Fuller-Pace, F. V., Egly, J. M., Coombes, R. C., and Ali, S. (2002) Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21, 4921-4931
16. Svensson, S., Jirström, K., Rydén, L., Roos, G., Emdin, S., Ostrowski, M. C., and Landberg, G. (2005) ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 24, 4370-4379
17. Weitsman, G. E., Li, L., Skliris, G. P., Davie, J. R., Ung, K., Niu, Y., Curtis- Snell, L., Tomes, L., Watson, P. H., and Murphy, L. C. (2006) Estrogen receptor-α phosphorylated at Ser-118 is present at the promoters of estrogen- regulated genes and is not altered due to HER-2 overexpression. Cancer Res. 66, 10162-10170
18. Teyssier, C., Belguise, K., Galtier, F., and Chalbos, D. (2001) Characterization of the physical interaction between estrogen receptor α and JUN proteins. J. Biol. Chem. 276, 36361-36369
19. Madeo, A., Vinciguerra, M., Lappano, R., Galgani, M., Gasperi-Campani, A., Maggiolini, M., and Musti, A. M. (2010) c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. Oncogene 29, 978-991
20. Loesch, M., and Chen, G. (2008) The p38MAPKstress pathway as a tumor suppressor or more? Front. Biosci. 13, 3581-3593
21. Hou, S., Lepp, A., and Chen, G. (2010) UCSD Nature Molecular Pages doi:10.1038/mp.a001720.01
22. Tang, J., Qi, X., Mercola, D., Han, J., and Chen, G. (2005) Essential role of p38γ in K-Ras transformation independent of phosphorylation. J. Biol. Chem. 280, 23910-23917
23. Qi, X., Tang, J., Loesch, M., Pohl, N., Alkan, S., and Chen, G. (2006) p38γmitogen-activated protein kinase integrates signaling cross-talk between Ras and estrogen receptor to increase breast cancer invasion. Cancer Res. 66, 7540-7547
24. Qi, X., Pohl, N. M., Loesch, M., Hou, S., Li, R., Qin, J. Z., Cuenda, A., and Chen, G. (2007) p38α antagonizes p38γ activity through c-Jun-dependent ubiquitin-proteasome pathways in regulating Ras transformation and stress response. J. Biol. Chem. 282, 31398-31408
25. Hou, S. W., Zhi, H. Y, Pohl, N., Loesch, M., Qi, X. M., Li, R. S., Basir, Z., and Chen, G. (2010) PTPH1 dephosphorylates and cooperates with p38γMAPK to increase ras oncogenesis through PDZ-mediated interaction. Cancer Res. 70, 2901-2910
26. Kukkonen-Macchi, A., Sicora, O., Kaczynska, K., Oetken-Lindholm, C., Pouwels, J., Laine, L., and Kallio, M. J. (2011) Loss of p38γ MAPK induces pleiotropic mitotic defects and massive cell death. J. Cell Sci. 124, 216-227
27. Wu, C. C., Wu, X., Han, J., and Sun, P. (2010) p38γ regulates UV-induced checkpoint signaling and repair of UV-induced DNA damage. Protein Cell 1, 573-583
28. Gross, E. A., Callow, M. G., Waldbaum, L., Thomas, S., and Ruggieri, R. (2002) MRK, a mixed lineage kinase-related molecule that plays a role in γ-radiation-induced cell cycle arrest. J. Biol. Chem. 277, 13873-13882
29. Qi, X., Hou, S., Lepp, A., Li, R., Basir, Z., Lou, Z., and Chen, G. (2011) Phosphorylation and stabilization of topoisomerase IIα protein by p38γmitogen-activated protein kinase sensitize breast cancer cells to its poisons. J. Biol. Chem. 286, 35883-35890
30. Avruch, J. (2007) MAP kinase pathways: the first 20 years. Biochim. Biophys. Acta 1773, 1150-1160
31. Meng, F., Zhang, H., Liu, G., Kreike, B., Chen, W., Sethi, S., Miller, F. R., and Wu, G. (2011) p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)- polymerase-1 inhibition in breast cancer. Neoplasia 13, 472-482
32. Rosenthal, D. T., Iyer, H., Escudero, S., Bao, L., Wu, Z., Ventura, A. C., Kleer, C. G., Arruda, E. M., Garikipati, K., and Merajver, S. D. (2011) p38γpromotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior. Cancer Res. 71, 6338-6349
33. Loesch, M., Zhi, H. Y, Hou, S. W, Qi, X. M., Li, R. S., Basir, Z., Iftner, T., Cuenda, A., and Chen, G. (2010) p38γ MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J. Biol. Chem. 285, 15149-15158
34. Li, Z., Jiang, Y., Ulevitch, R. J., and Han, J. (1996) The primary structure of p38γ: a new member of p38 group of MAP kinases. Biochem. Biophys. Res. Commun. 228, 334-340
35. Qi, X., Borowicz, S., Pramanik, R., Schultz, R. M., Han, J., and Chen, G. (2004) Estrogen receptor inhibits c-Jun-dependent stress-induced cell death by binding and modifying c-Jun activity in human breast cancer cells. J. Biol. Chem. 279, 6769-6777
36. Chen, G., and Waxman, D. J. (1995) Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem. Pharmacol. 49, 1691-1701
37. Zhi, H. Y, Hou, S. W, Li, R. S, Basir, Z., Xiang, Q., Szabo, A., and Chen, G. (2011) PTPH1 cooperates with vitamin D receptor to stimulate breast cancer growth through their mutual stabilization. Oncogene 30, 1706-1715
38. Chen, G., Hitomi, M., Han, J., and Stacey, D. W. (2000) The p38 pathway provides negative feedback for Ras proliferative signaling. J. Biol. Chem. 275, 38973-38980
39. Robinson, M. J., Stippec, S. A., Goldsmith, E., White, M. A., and Cobb, M. H. (1998) A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr. Biol. 8, 1141-1150
40. Creighton, C. J., Hilger, A. M., Murthy, S., Rae, J. M., Chinnaiyan, A. M., and El-Ashry, D. (2006) Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors. Cancer Res. 66, 3903-3911
41. Henrich, L. M., Smith, J. A., Kitt, D., Errington, T. M., Nguyen, B., Traish, A. M., and Lannigan, D. A. (2003) Extracellular signal-regulated kinase 7, a regulator of hormone-dependent estrogen receptor destruction. Mol. Cell. Biol. 23, 5979-5988
42. Zhi, H., Yang, X. J., Kuhnmuench, J., Berg, T., Thill, R., Yang, H., See, W. A., Becker, C. G., Williams, C. L., and Li, R. (2009) SmgGDS is upregulated in prostate carcinoma and promotes tumour phenotypes in prostate cancer cells. J. Pathol. 217, 389-397
43. Li, L., Li, Z., Howley, P. M., and Sacks, D. B. (2006) E6AP and calmodulin reciprocally regulate estrogen receptor stability. J. Biol. Chem. 281, 1978-1985
44. Angel, P., Hattori, K., Smeal, T., and Karin, M. (1988) The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell 55, 875-885
45. Albanese, C., D'Amico, M., Reutens, A. T., Fu, M., Watanabe, G., Lee, R. J., Kitsis, R. N., Henglein, B., Avantaggiati, M., Somasundaram, K., Thimmapaya, B., and Pestell, R. G. (1999) Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J. Biol. Chem. 274, 34186-34195
46. Shang, Y., and Brown, M. (2002) Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468
47. Linderholm, B. K., Hellborg, H., Johansson, U., Skoog, L., and Lehtiö, J. (2011) Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer. Breast Cancer Res. Treat. 125, 457-465
48. Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., and Dowsett, M. (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23, 2469-2476
49. Perdiguero, E., Ruiz-Bonilla, V., Gresh, L., Hui, L., Ballestar, E., Sousa- Victor, P., Baeza-Raja, B., Jardí, M., Bosch-Comas, A., Esteller, M., Caelles, C., Esteller, M., Caelles, C., Serrano, A. L., Wagner, E. F., and Muñoz- Cánoves, P. (2007) Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38α in abrogating myoblast proliferation. EMBO J. 26, 1245-1256
50. Moran, N. (2011) p38 kinase inhibitor approved for idiopathic pulmonary fibrosis. Nat. Biotechnol. 29, 301
51. Ozes, O., Blatt, L. M., and Seiwert, S. D. (August 5, 2008) U. S. Patent 7,407,973 B2, 1-46
52. Oh, A. S., Lorant, L. A., Holloway, J. N., Miller, D. L., Kern, F. G., and El-Ashry, D. (2001) Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells. Mol. Endocrinol. 15, 1344-1359
53. Oyama, M., Nagashima, T., Suzuki, T., Kozuka-Hata, H., Yumoto, N., Shiraishi, Y., Ikeda, K., Kuroki, Y., Gotoh, N., Ishida, T., Inoue, S., Kitano, H., and Okada-Hatakeyama, M. (2011) Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer. J. Biol. Chem. 286, 818-829
54. Pan, X., Zhou, T., Tai, Y. H., Wang, C., Zhao, J., Cao, Y., Chen Y., Zhang, P. J., Yu, M., Zhen, C., Mu, R., Bai, Z. F., Li, H. Y., Li, A. L., Liang, B., Jian, Z., Zhang, W. N., Man, J. H., Gao, Y. F., Gong, W. L., Wei, L. X., and Zhang, X. M. (2011) Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat. Med. 17, 708-714
55. Mandlekar, S., Yu, R., Tan, T. H., and Kong, A. N. (2000) Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen- induced apoptosis of human breast cancer cells. Cancer Res. 60, 5995-6000
56. Lassar, A. B. (2009) The p38 MAPK family, a pushmi-pullyu of skeletal muscle differentiation. J. Cell Biol. 187, 941-943
57. Osborne, C. K., Schiff, R., and Shou, J. (July 22, 2008) U. S. Patent 7,402,402, B2, 1-13